KT
Kamal Therapeutics, Inc.
SEC filingPharmaceuticals · Hingham, MA
Amount raised$13.8Msold at filing
Total offering$17.3M$3.5M still open
Investors in the raise41count reported to the SEC
FiledNov 24, 2025first sale Nov 10, 2025
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Mark de SouzaExecutive Officer, Director
Philip ReillyDirector
John ParkerDirector
Executive officers, directors and promoters as listed on the Form D.